RAC

0.00%

$1.69 race oncology ltd

Cardioprotection thread, page-562

First 562 Last

Share
Profile

Follow
HeyLine

2,738 Posts.

666

31/05/24

18:57

Post #: 74110813
Share

Originally posted by JBeez_: ↑

"Furthermore, although the reviewed studies have consistently shown the cardioprotective effects of SGLT2 inhibitors against cancer treatment–related cardiotoxicity in tumor-free models, none has yet concurrently demonstrated the cardioprotective and the anticancer effects of SGLT2 inhibitors in tumor-bearing model"

Definitely a space to watch, the SGLT2s are ubiquitous in cardiorenal disease and form part of the fundamental 4 pillars of heart failure treatments along with the ARNIs, beta-blockers and MRAs. They will get great physician buy-in if they can demonstrate cardioprotection in an RCT.

Of course the holy-grail is cardioprotection AND anti-cancer synergy which is yet to be proven in SGLT2s but this could pose a threat to bisantrene if proven.

Gret find @HeyLine

Expand

Thanks Beez. I found the MOA section intriguing hence me posting. Appreciate your reply.

Originally posted by RaceOncology: ↑

SGLT2 inhibitors are not going to prove a threat to bisantrene for a number of reason beyond that they haven't even been shown to work as an anticancer agent in animal models. The major one is the anticancer activity needs to be as broadly active as doxorubicin and not targeted to a tiny fraction of all cancers like SGLT2.

The second is nobody is going to pay for the trials to prove out SGLT2 inhibitors in the clinic as there is no way to protect against generic competition.

The third is oncologists are so reluctant to change anything to do with chemotherapy that the first drug to capture the anticancer cardioprotective market will be impossible to displace. This is the reason we can't sell bisantrene as a better and safer alternative to doxorubicin even though it is clinically proven to provide longer life expectancy than doxorubicin in breast cancer patients with far fewer side effects. This is sad, but the reality of chemotherapy today.

Expand

Thanks T. Knew you'd come up with the goods.

RAC Price at posting: $1.48 Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

There are more pages in this discussion • 345 more messages in this thread...

First 562 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.000(0.00%)		Mkt cap ! $288.0M

Open	High	Low	Value	Volume
$1.66	$1.69	$1.57	$387.6K	237.1K

Buyers (Bids)

No.	Vol.	Price($)
1	807	$1.63

Sellers (Offers)

Price($)	Vol.	No.
$1.69	2376	1

View Market Depth

No.	Vol.	Price($)
1	807	1.630
1	4000	1.600
2	2300	1.580
1	636	1.570
1	6000	1.560

Price($)	Vol.	No.
1.690	2376	1
1.730	11500	1
1.735	3313	1
1.750	2000	1
1.790	1000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

RAC (ASX) Chart

Cardioprotection thread, page-562

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Cardioprotection thread, page-562

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News